BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/17/2024 5:55:52 AM | Browse: 192 | Download: 834
 |
Received |
|
2024-04-19 04:04 |
|
Peer-Review Started |
|
2024-04-19 04:04 |
|
First Decision by Editorial Office Director |
|
2024-06-18 03:43 |
|
Return for Revision |
|
2024-06-18 03:43 |
|
Revised |
|
2024-06-22 07:54 |
|
Publication Fee Transferred |
|
2024-07-01 08:07 |
|
Second Decision by Editor |
|
2024-06-28 02:50 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-06-28 09:51 |
|
Articles in Press |
|
2024-06-28 09:51 |
|
Edit the Manuscript by Language Editor |
|
2024-07-10 01:16 |
|
Typeset the Manuscript |
|
2024-07-12 02:07 |
|
Publish the Manuscript Online |
|
2024-07-17 05:55 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Returning from the afterlife? Sotorasib treatment for advanced KRAS mutant lung cancer: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ming-Xing Wang, Pei Zhu, Yue Shi, Qing-Ming Sun and Wan-Hui Dong |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Wan-Hui Dong, MD, Chief Doctor, Department of Medical Oncology, Lu'an Hospital of Traditional Chinese Medicine, No. 76 Renmin Road, Lu'an 237000, Anhui Province, China. dongwanhui@laszyy.cn |
| Key Words |
Non-small cell lung cancer; Sotorasib; KRAS G12C; Targeted therapy; Advanced carcinoma; Case report |
| Core Tip |
In this study, we demonstrate the efficacy of Sotorasib in treating advanced non-small cell lung cancer with the KRAS G12C mutation. A patient diagnosed with stage IVB adenocarcinoma, exhibiting pelvic and bone metastases, showed a significant improvement in clinical symptoms post-Sotorasib treatment, with no severe side effects observed. This case highlights the potential of targeted therapies in personalized cancer treatment, emphasizing the importance of genomic profiling for therapeutic decision-making. |
| Publish Date |
2024-07-17 05:55 |
| Citation |
Wang MX, Zhu P, Shi Y, Sun QM, Dong WH. Returning from the afterlife? Sotorasib treatment for advanced KRAS mutant lung cancer: A case report. World J Clin Cases 2024; 12(25): 5805-5813 |
| URL |
https://www.wjgnet.com/2307-8960/full/v12/i25/5805.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v12.i25.5805 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
